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Ku
DNA-PKcsNon-homologous end joining (NHEJ) is one of the major pathways that repairs double-stranded DNA breaks
(DSBs). Activation of DNA-PK is required for NHEJ. However, the mechanism leading to DNA-PKcs activation
remains incompletely understood. We provide evidence here that the MEK–ERK pathway plays a role in
DNA-PKcs-mediated NHEJ. In comparison to the vehicle control (DMSO), etoposide (ETOP)-induced DSBs
in MCF7 cells were more rapidly repaired in the presence of U0126, a speciﬁc MEK inhibitor, based on the re-
duction of γH2AX and tail moments. Additionally, U0126 increased reactivation of luciferase activity, which
resulted from the repair of restriction enzyme-cleaved DSBs. Furthermore, while inhibition of ERK activation
using the dominant-negative MEK1K97M accelerated the repair of DSBs, enforcing ERK activation with the
constitutively active MEK1Q56P reduced DSB repair. In line with MEK activating ERK1 and ERK2 kinases,
knockdown of either ERK1 or ERK2 increased DSB repair. Consistent with the activation of DNA-PKcs being
required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knock-
down of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs. Conversely, enforcing ERK activation
by MEK1Q56P reduced ETOP-initiated DNA-PKcs activation. Taken together, we demonstrate that ERK
reduces NHEJ-mediated repair of DSBs via attenuation of DNA-PKcs activation.
Crown Copyright © 2012 Published by Elsevier B.V. All rights reserved.1. Introduction
Double-stranded DNA breaks (DSBs) are the most toxic form of
DNA lesions. DSBs can be generated endogenously during cellular
processes including immunoglobin gene rearrangement [V(D)J re-
combination] and meiotic recombination as well as exogenously by
DNA damage reagents such as ionizing radiation (IR) and etoposide,
a topoisomerase poison [1,2]. Compromising the process of DSB re-
pair could result in radiation-sensitive and severe combined immune
deﬁciency (SCID) in humans (RS-SCID) [3,4] and in mice [5,6].
DSBs are repaired by two major pathways, homologous recombina-
tion (HR) and non-homologous end joining (NHEJ) [2]. NHEJ, which is
not restricted to speciﬁc phases of the cell cycle, is the major pathway
that repairs IR-induced DSBs and the DSBs that are not associatedMaternity and Child Healthcare
18100. Tel.:+86 13088883678.
, 50 Charlton Ave East, Hamilton,
ax: +1 905 521 6181.
amut@mcmaster.ca (D. Tang).
12 Published by Elsevier B.V. All rigwith replication [1,2]. The core machinery of NHEJ consists of DNA-PK
(the DNA-dependent protein kinase), end processing factors, and the
XRCC4/DNA ligase IV complex [7,2]. The DNA-PK complex forms
when the catalytic subunit (DNA-PKcs) binds to DSBs and the Ku
(Ku70/80 heterodimer) proteins [2]. The ﬁrst event of a NHEJ reaction
is Ku-mediated recognition of DSBs, which leads to the association of
DNA-PKcs with both Ku and double-stranded (ds) DNA ends, resulting
in substantial increases in the protein kinase activity of DNA-PKcs [7,2].
While it is well documented that activation of DNA-PKcs is essen-
tial in the initiation of the NHEJ process [8,2], mechanisms governing
DNA-PKcs activation is less understood. DNA-PKcs belongs to the
family of PI3 kinase related kinases (PIKKs), which include ATM,
ATR, and DNA-PKcs. PIKKs possess typical structural features, includ-
ing a FAT, a kinase, and a C-terminal FATC domain [9]. These features
underlie as to why activation of PIKKs involves binding to speciﬁc
proteins and interaction with DNA lesions [10]. DNA-PKcs activation
is primarily mediated by binding to Ku in the presence of dsDNA
ends [11,12]. In vitro interaction with DNA-bound Ku is sufﬁcient to
activate DNA-PKcs [11,13]. Activation of DNA-PKcs results in auto-
phosphorylation at residues within two major clusters, the ABCDEhts reserved.
91F. Wei et al. / Biochimica et Biophysica Acta 1833 (2013) 90–100and PQR cluster [14,8,15], as well as at threonine (T) 3905 in the
T-loop located in the kinase domain [16]. These autophosphorylation
events cause conformational changes in DNA-PK, which mediates the
subsequent steps in DSB repair [17].
While in vitro Ku and dsDNA ends are sufﬁcient to activate DNA-
PKcs, it is most likely that activation of DNA-PKcs in vivo requires addi-
tional factors. However, the identities of these factors remain largely
unknown. We and others have recently demonstrated that the MEK–
ERK pathway plays a role in DDR. ERK1 and ERK2 are members of the
mitogen-activated protein kinase (MAPK) family [18] and are activated
by the upstream kinases, MEK1 and MEK2 [19]. Activation of ERK ki-
nases was observed in DDR that was induced by multiple DNA damage
reagents [20–24]. While ERK activity facilitates DNA damage-induced
cell cycle arrest or apoptosis in several mammalian cell lines and
Drosophila [22,23,25–28], ERK activation also prevents DNA damage-
induced apoptosis [24,29,30]. ERK mediates these DDR events down-
stream of either ATM [31] or ATR [26]. Experimental evidence also
exists to place ERK upstream of ATM and ATR activation during
DDR. It has been reported that the MEK–ERK pathway facilitates DNALaminB
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whether ERK plays a role in DNA-PK dependent NHEJ remains unclear.
We report here that inhibition of ERK activation via a variety of
means enhances the repair of etoposide-induced DSBs by the sensiti-
zation of DNA-PKcs activation. Conversely, enforcing ERK activation
using the constitutively active MEK1Q56P reduces NHEJ-mediated re-
pair of DNA lesions which is associated with attenuation of DNA-PKcs
activation. Taken together, we demonstrate here that ERK kinases at-
tenuate DSB repair by reducing DNA-PKcs activation.
2. Material and methods
2.1. Materials and cell lines
Etoposide and Neocarzinostatin (NCS) were purchased from Sigma.
MEK1 inhibitor U0126 was obtained from Sigma and dissolved in
DMSO. MCF7 cells were purchased from ATCC and cultured in DMEM,
supplemented with 10% FBS. The pGL2-control vector was purchased
from Promega.EV
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cells. (C) ERK1 or ERK2 in MCF7 cells was stably knocked-down using speciﬁc shRNA (top panel) and the kinetics of ETOP-induced DSBs was then examined by comet assay and
analyzed. Experiments were repeated three times. *: statistically signiﬁcant (pb0.05) in comparison to Ctrl cells.
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Hairpin-based ERK1 andERK2 shRNAplasmids (pSUPER-Erk1shRNA,
pSUPER-Erk2shRNA) were reported to knockdown ERK1 and ERK2 in
multiple myeloma cells [34]. These constructs were kindly provided by
Dr. Chatterjee. We co-transfected MCF7 cells with pSUPER, pSUPER-
Erk1shRNA, or pSUPER-Erk2shRNA, which do not possess an antibi-
otic selection marker, together with pcDNA3 (containing a Geneticin
or G418 selection marker) at a ratio of 1:10 (pcDNA3: pSUPER,
pSUPER-Erk1shRNA, or pSUPER-Erk2 shRNA). Cells were cultured
in DMEM supplemented with G418 (1.5 mg/ml) for 3–4 weeks. Sur-
viving cell colonies were examined for the knockdown of ERK1 and
ERK 2 by western blot. Cells transfected with pSUPER+pcDNA3
were named as MCF7 Ctrl (control) cells.2.3. Cell lysis and western blot
Cell lysates were prepared in a buffer containing 20 mM Tris
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
25 mM sodium pyrophosphate, 1 mM NaF, 1 mM β-glycerophosphate,
0.1 mM sodium orthovanadate, 1 mM PMSF, 2 μg/ml leupeptin and
10 μg/ml aprotinin. Total cell lysate containing 50 μg protein was sepa-
rated on SDS-PAGE gel and transferred onto Immobilon-P membranes
(Millipore). Membranes were blocked with 5% skim milk, followed
by incubation with the indicated antibodies overnight at 4 °C. Sig-
nals were detected using an ECL Western Blotting Kit (Amersham).
Primary antibodies and concentrations used are indicated as follows:
anti-DNA-PKcs (1:1000; Abcam), anti-phospho-S2056 DNA-PKcs
(1:1000; Abcam), anti-H2AX (1:1000; Cell Signalling), anti-γH2AX
93F. Wei et al. / Biochimica et Biophysica Acta 1833 (2013) 90–100(1:1000; Upstate), anti-lamin B (1:1000; Santa Cruz), anti-Ku70
(1:1000; Abcam), and anti-Ku80 (1:10,000; Abcam).
2.4. Immunoﬂuorescence staining
Immunoﬂuorescence stainingwas carried out by ﬁxing cells with 4%
paraformaldehyde for 15 min. The primary antibodies, anti-γH2AX
(Upstate; 0.5 μg/ml), anti-phospho-S2056 DNA-PKcs (1:100; Abcam),
and anti-Ku70 (1:100; Abcam), were added to the slides at 4 °C
overnight, which was followed by incubation with the indicated sec-
ondary antibodies [Rhodamine-Donkey anti-rabbit IgG (1:200, Jackson
Immuno Research Lab)] for 1 h at room temperature. The slides were
subsequently covered with the VECTASHIELD mounting medium with
DAPI (VECTOR Lab Inc., Burlingame, CA94010). Images were taken
using a ﬂuorescentmicroscope (Carl Zeiss, Axiovert 200) and processed
by Photoshop and CorelDRAWx4.
2.5. Alkaline comet assay
Comet assay was performed following a published procedure
[35]. Brieﬂy, after speciﬁc treatments, cells were mixed with low
melting point (LMP) agarose, applied to a 0.7% LMP agarose-coated
slide, and lysed in a lysis buffer [2.5 M NaCl, 100 mM EDTA, 10 mM
Tris (pH 10.0), 1% sodium lauroyl sarcosinate, 1% Triton X-100, and
10% DMSO] for 1 h at 40 °C in the dark. Unwinding of DNA was
performed in running buffer (300 mM NaOH, 1 mM EDTA) for 40 min
at 40 °C in dark, followed by electrophoresis in the same buffer at 25 V
(0.7 V/cm) for 20 min at 40 °C in dark. Slides were neutralized in a buff-
er containing 0.4 M Tris–HCl (pH7.5) for 15 min with changes everySv40 Prom luciferase
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Fig. 3. Attenuation of ERK activation enhances NHEJ-mediated repair of DSBs. (A) Illustration
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(B) MCF7 cells were pre-treated with DMSO or U0126 (50 μM) for 30 min, and then transfec
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quired with a ﬂuorescent microscope (Carl Zeiss, Axiovert 200). At
least 100 nuclei were analyzed for tail moment using the comet assay
software project.
2.6. Ex vivo NHEJ assay
This assay was performed according to the published methodolo-
gy [36]. In brief, pGL2-control (pGL2) construct was digested with ei-
ther HindIII or EcoRI to completion, which was conﬁrmed by DNA
electrophoresis. Digested DNA was gel-puriﬁed. MCF7 cells were
transiently transfected, using the TransIT-2020 Transfection reagent
(Mirus Bio LLC), with undigested pGL2/β-Gal (2:1) or digested
pGL2/β-Gal in triplicate for 48 h. Luciferase and β-Gal activity were
determined using a commercial kit (Promega). Luciferase activity
was ﬁrst normalized against the respective β-Gal activity. Normalized
luciferase activity derived from restriction enzyme-digested pGL2
was then expressed as the percentage of the normalized luciferase ac-
tivity derived from uncut pGL2. Experiments were repeated three
times. Means and standard errors were calculated using Excel.
2.7. Cell survival assay
The designated cells were seeded in duplicate at 2×104cells/well
in 6-well plates for 24 h. Cells were then treated with DMSO (mock
treatment) or ETOP at the designated doses for 8 h, followed by cul-
turing in untreated medium for one week before the mock-treated
cells became conﬂuent. Surviving cells were then stained with crystal
violet (0.5%). Three empty wells were also stained as background.DMSO U0126
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a spectrometer at 550 nm. Speciﬁc staining was then derived by the
subtraction of background staining.
2.8. Statistical analysis
Statistical analysis was performed using student t-test and pb0.05
was considered statistically signiﬁcant.
3. Results
3.1. Attenuation of ERK activation reduces etoposide-induced DSBs in
MCF7 cells
Etoposide (ETOP) stabilizes topoisomerase II-associated DNA breaks,
and thereby preventing topoisomerase II-mediated ligation of cleaved
DNA ends, resulting in the production of DSBs in the cell [37]. We have
recently observed that knockdown of either ERK1 or ERK2 signiﬁcantly
reduces γH2AX in MCF7 cells during an 8-hour treatment with ETOP
[32]. As γH2AX is a well regarded surrogate marker of DSBs, the above
observations suggest thatmodulation of ERK activation affects the accu-
mulation or repair of DSBs. To address this possibility, we have exam-
ined the kinetics of ETOP-induced γH2AX expression under different
conditions of ERK activation. Evidenced by the induction of γH2AX,10 μM ETOP induces DSBs (Fig. 1A). When the constitutively active
MEK1Q56P was ectopically expressed in MCF7 cells, ERK activation
was elevated (Fig. 1B) and 10 μM ETOP induced more γH2AX (Fig. 1C,
Supplementary Fig. 1). Conversely, when ERK activation was reduced
in MCF7 MEK1K97M cells in comparison to MCF7 EV cells (Fig. 1B),
10 μM ETOP induced less γH2AX ((Fig. 1C, Supplementary Fig. 1).
However, we noticed that at the 0.5 h treatment with 10 μM ETOP,
neither MEK1Q56P nor MEK1K97M MCF7 cells contained signiﬁ-
cantly different amounts of γH2AX than EV MCF7 cells (Fig. 1C). Col-
lectively, these observations reveal that ERK activity facilitates the
accumulation of γH2AX, indicative of the accumulation of DSBs.
To quantify DSB accumulation, we measured the tail moments
using the comet assay under most widely used alkaline condition. Al-
though the comet assay was believed to speciﬁcally detect single-
stranded and double-stranded breaks under alkaline and neutral
conditions, respectively, evidence presented in the recent Interna-
tional Comet Assay conference revealed that this was a miscon-
ception as the comet assay simply detects DNA breaks, both single-
stranded and double-stranded breaks, performed at both alkaline
and neutral conditions [38,39]. Consistent with this notion, alkaline
comet assay is commonly used to detect DSBs [40–42]. In compari-
son with the vehicle control (DMSO), U0126 (the speciﬁc MEK inhib-
itor) does not affect ETOP-induced DSBs in the ﬁrst 30 min of the
treatment (Fig. 2A). However, U0126 reduces ETOP-induced DNA
95F. Wei et al. / Biochimica et Biophysica Acta 1833 (2013) 90–100breaks upon prolonged treatment (Fig. 2A, typical image shown on
right panel). Similar results were also obtained when the dominant
negative MEK1K97M was used. As expected, MEK1K97M inhibited
the activation of ERK1 and ERK2 (Fig. 1B). In comparison to EV
(empty vector) cells, MEK1K97M cells showed reduction of DNA breaks
after treatment beyond 45 min (Fig. 2B). Conversely, enforced ERK ac-
tivation by overexpression of the constitutively active MEK1Q56P in
MCF7 cells (Fig. 1B) yielded comparable levels of DSBs in comparison
with EV transfected cells at early phases of ETOP treatment, butA B
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3.2. Inhibition of ERK activation enhances NHEJ-mediated end-joining
activity
The above observations strongly suggest that ERK kinase activity
negatively regulates the repair of ETOP-induced DSBs. To directly
test this possibility, we measured NHEJ-mediated end-joining activity
using an ex vivo assay (Fig. 3A) [36]. This type of ex vivo assay is
widely used to assay cells' NHEJ capacity [36,43,44]. The assay detects
the repair of a luciferase reporter construct (pGL2) that is cleaved by
speciﬁc restriction enzymes (Fig. 3A). Repair of HindIII cleavage in the
linker region between the SV40 promoter and the luciferase coding
region enables luciferase expression even in the presence of muta-
tions (Fig. 3A). Repair of EcoR1 cleavage within the lucifease coding
region needs to be precise in order to produce functional luciferase
(Fig. 3A). Therefore, this assay measures total (HindIII cleavage) and
precise (EcoRI cleavage) end-joining activities (Fig. 3A) [36]. Since
there is no intact homologous DNA strand available, this ex vivo
assay largely measures the cellular NHEJ activity [36].
When using this assay to detect NHEJ-mediated end-joining activity,
it was found that U0126 signiﬁcantly increased both overall and precise
end-joining activities in comparison to DMSO (Fig. 3B). While over-
expression of the dominant negative MEK1K97M enhanced end-
joining activity in comparison to EV cells, ectopic expression of the con-
stitutively active MEK1Q56P reduced the end-joining activity (Fig. 3C).
Furthermore, knockdown of either ERK1 or ERK2 also enhanced the re-
pair of restriction enzyme cleavedDNAbreaks (Fig. 3D). Taken together,
we demonstrated that attenuation of ERK activation enhances cellular
NHEJ activity. However, we could not distinguish the impact of ERK ac-
tivation on the activity of overall end-joining versus that of preciseend-joining. This might be attributable to the nature of this assay. As
the breaks produced by HindIII and EcoRI are simple and competent
for ligation, repair of these DSBs may not require the processing of
dsDNA ends. Therefore, repair of these breaks may be much more pre-
cise than the repair of DSBs induced by DNAdamage reagents. This pos-
sibility is supported by observations reported by others [36].
3.3. ERK activity reduces the repair of ETOP-induced DSBs
To examine whether attenuation of ERK activation facilitates the re-
pair of ETOP-induced DSBs, MCF7 cells were treated with 10 μM ETOP
for 30 min, which produces readily detectable tail moments examined
by comet assay (Supplementary Fig. 3), followed by a period of chase
(i.e. removal of ETOP) to allow DSB repair. In comparison with DMSO,
50 μM U0126, which potently inhibits ERK activation (Fig. 2A,inset),
signiﬁcantly enhanced the reduction of tail moments (Fig. 4A). Inhi-
bition of ERK activation in cells expressing the dominant negative
MEK1K97M also promoted the reduction of tail moments compared
to EV cells (Fig. 4B). Conversely, the constitutively active MEK1Q56P,
which activates ERK, slowed down the decrease in tail moments in
comparison to EV (Fig. 4B). Consistent with these observations, knock-
down of either ERK1 or ERK2 also promoted the repair of ETOP-induced
DSBs, based on the observed reduction of tail moments in ERK1 shRNA
and ERK shRNA cells in comparison to Ctrl cells (Fig. 4C).
To consolidate the above observations, we were able to show that
while the dominant negative MEK1K97M accelerated the decreases of
γH2AX during the periods of an 8 hour chase, the constitutively active
MEK1Q56P signiﬁcantly reduced this process in comparison to EV
((Fig. 5A, Supplementary Fig. 4). Furthermore, although a 30-minute
treatment with 10 μM ETOP produced comparable levels of γH2AX in
Ctrl, ERK1 shRNA, and ERK2 shRNA cells (Fig. 5B), γH2AX was reduced
in an accelerated fashion in ERK1 shRNA and ERK2 shRNA cells
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the percentage of cells showing γH2AX foci was also reducedmore rap-
idly in ERK1 shRNA and ERK2 shRNA cells than in Ctrl cells ((Fig. 5C,
Supplementary Fig. 5). At the 8 hour chase, a number of cells displaying
γH2AX fociwere greatly reduced in all cell lines, whichmay be attribut-
able to no signiﬁcant differences being detected then among all cell
lines (Fig. 5C).
To address whether enhancing DSB repair promotes cell survival
following ETOP treatment, we treated Ctrl, ERK1 shRNA, and ERK2
shRNA cells with increasing doses of ETOP for 8 h and then examined
the cell's survival capacity using a clonogenic assay. In comparison to
the respective mock (DMSO) treatments, ERK1 shRNA and ERK2
shRNA cells survived better than Ctrl cells (Fig. 5D).
We subsequently demonstrated that ERK activity-mediated re-
duction of DSB repair is not limited to DSBs induced by ETOP. NCS
(Neocarzinostatin) is a well-demonstrated radiomimetic drug. At
50 ng/ml, NCS clearly induced DSBs based on the appearance of
γH2AX (Fig. 6A). While at the 30 minute time point, NCS induced com-
parable amount of γH2AX in MCF7 cells treated with either DMSO or
U0126 (Fig. 6B), during the chase period, inhibition of ERK activation
by U0126 signiﬁcantly accelerated the reduction of γH2AX, demon-
strating that ERK activity reduces the repair of NCS-induced DSBs (Sup-
plementary Fig. 6). Taken together, we provide compelling evidence
that ERK activation negatively impacts the repair of DSBs.Ku70
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to EV cells (right panel).3.4. Inhibition of ERK activation enhances ETOP-induced activation of
DNA-PKcs
As NHEJ is one of the major process of DSB repair [2] and because
ETOP-induced DSBs are repaired by NHEJ [45], the data presented
above collectively support the notion that ERK activation reduces
the repair of DSBs via affecting the NHEJ pathway. Activation of
NHEJ starts upon the recognition of DSBs by Ku, which results in
the activation of DNA-PKcs [2]. We thus reasoned that ERK activation
may reduce either the recognition of DSBs by Ku or the subsequent
DNA-PKcs activation. As ETOP induces comparable accumulation of
Ku in the nuclei in Ctrl, shRNA, and ERK2 shRNA cells (Supplementa-
ry Fig. 7), we therefore focused on the latter possibility.
Phosphorylation of DNA-PKcs at S2056 is mediated by DNA-PKcs
and is therefore widely used to detect the activation of DNA-PKcs
[16,17]. While inhibition of ERK activation by U0126 does not alter the
expression of DNA-PKcs and the Ku proteins (Fig. 7A, left panel),
U0126 signiﬁcantly enhances DNA-PKcs activation compared to DMSO
treatment (Fig. 7A). In line with these observations, inhibition of ERK
activation by the dominant negative MEK1K97M increased ETOP-
induced DNA-PKcs activation and conversely enforced activation of
ERK by expressing the constitutively active MEK1Q56P reduced this
event (Fig. 7B). Furthermore, knockdownof either ERK1or ERK2 also el-
evated ETOP-induced activation of DNA-PKcs (Fig. 8A). In comparison0
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stantial increase in the nuclear foci of S2056 phosphorylated DNA-
PKcs (Fig. 8B). Additionally, more number of ERK1 shRNA or ERK2
shRNA cells displayed the nuclear foci of S2056-phosphorylated DNA-
PKcs than Ctrl cells (Fig. 8C, Supplementary Fig. 8).
4. Discussion
Accumulating evidence reveals the involvement of the MEK–ERK
pathway in the activation of DNA damage checkpoints during DDR
[31,26]. Adding to this knowledge, we demonstrated that the MEK–
ERK pathway, surprisingly, reduces NHEJ-mediated repair of DSBsvia attenuation of DNA-PKcs activation. As ETOP induced DSBs by
“poisoning” topoisomerase II [37], it is possible that ERK kinase activ-
ity may rescue topoisomerase II from being poisoned by ETOP, and
thereby attenuating ETOP-induced DSBs. However, our research
clearly excluded this possibility. 1) Upon exposure of ETOP for
30 min, comparable amounts of DSBs were detected in cells with or
without ERK kinase activation being altered (Figs. 2, 4, 5); 2) It is in
the chase phase that ERK activity was found to reduce DSB repair
(Figs. 4, 5); 3) ERK activity also attenuates the repair of NCS-induced
DSBs (Fig. 6). Collectively, we have demonstrated that ERK activity de-
lays NHEJ-mediated repair of DSBs. Our research is consistent with a re-
cent report showing that inhibition of p38 MAPK stimulates the repair
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ing to propose that MAP kinases in general attenuate the repair of DSBs
via either NHEJ (ERK MAPK, this study) or homologous recombination
(p38 MAPK) [31].
ERK activation via oncogenic RAF has been reported to facilitate
HR [31]. As HR occurs in late S and G2 phases and because ERK ki-
nases are well known to promote cell cycle progression, it remains
to be seen whether ERK kinases facilitate HR by directly affecting
the HRmachinery or by indirectly accelerating cell cycle progression.
Although it has been reported that the MEK–ERK pathway contribut-
ed to EGFR-sensitized NHEJ- and HR-mediated repair of IR-induced
DSBs in A549, H1299, and U87 cells [46,47], it was not clear whether
this was caused by interplays between the MEK–ERK system and the
rest of EGFR-activated signalling network. Additionally, as both re-
ports relied solely on using inhibitors, the concept that the MEK–
ERK pathway enhances the repair of IR-induced DSBs via NHEJ
needs to be conﬁrmed. However, it is also possible that the differ-
ences between their studies and our investigation may be attribut-
able to different cell lines and DSB-inducing reagents being used.
Nonetheless, in our research, we demonstrated that ERK reduces
NHEJ via inhibition of DNA-PKcs activation via a variety of ap-
proaches, including using U0126, dominant negative MEK1K97M,
constitutively active MEK1Q56P, and knockdown of either ERK1 or
ERK2. Although we cannot exclude the possibility that ERK may
also reduce steps downstream of DNA-PK in the NHEJ cascade, our
observation that ERK kinases affect the activation of DNA-PKcs is
consistent with their involvement in activation of other PIKK mem-
bers, ATM [31,32] and ATR [25,33].
While individual mechanisms are certainly in place to activate
ATM, ATR, and DNA-PKcs, their activation shares core features:
interaction with speciﬁc binding partners and association with
DNA lesions [10]. As threshold levels of ERK activity are required
for the proper recruitment of ATM and ATR to DNA lesions [31–33],
it is tempting to propose that ERK activity may either directly or in-
directly reduce the association of DNA-PKcs with DNA-associated
Ku. Alternatively, by attenuating DNA-PKcs activation, ERK activity
may reduce the dissociation of DNA-PKcs from dsDNA ends. This is
because autophosphorylation induces conformation changes in
DNA-PKcs [17], leading to its dissociation from dsDNA ends [13,48],
a critical event that is required for NHEJ [2]. Further research, howev-
er, is needed to address the underlying mechanisms responsible for
ERK-mediated attenuation of DNA-PKcs activation.
Although PIKKs are critical kinases in regulating DDR and their acti-
vation coordinates the execution of DDR in terms of damage repair and
activation of cell cycle checkpoints [49,50], it is, however, unclear how
this coordination is achieved. It is, thus, intriguing to see that ERK ki-
nases facilitate the activation of ATM and ATR [31–33], and at the
same time attenuates the activation of another PIKK member, DNA-
PKcs. As ATM and DNK-PKcs are both activated by DSBs [51,2], we
may envisage a scenario in which ERK kinases differentially regulate
the activation of DNA-PKcs and ATM. Activation of ATM is mediated
by MRN (MRE11/RAD50/NBS1) [52–54]. The MRN complex recognizes
DSBs to initiate HR that takes place in S andG2 phases, while NHEJ is not
generally restricted to speciﬁc phases of the cell cycle [2]. ERK kinases
promote cell cycle progression and facilitate DSB-induced G2/M arrest
[32]. As DSBs are repaired mainly by either HR or NHEJ [2], it is thus
plausible that ERK kinases, upon activation by DNA damage, slow
down NHEJ-mediated repair of DSBs via reducing DNA-PKcs activation
in order to leave DSBs to be repaired by HR. As HR is an error-free pro-
cess in comparisonwith the error-prone process of NHEJ-mediated DSB
repair [55,2], this settingwould therefore enhance the ﬁdelity of DSB re-
pair. Interestingly, this hypothesis is consistent with the observations
that ERK kinases facilitate HR-mediated repair of DSBs [31].
Regardless of what might be the biological impact of the observed
differential regulation of PIKK activation by the ERK kinases during
DDR, it seems a common theme that the MEK–ERK pathway regulatesthe proper activation of PIKK members, including ATM, ATR, and
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